問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Hematology & Oncology

Division of General Surgery

Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

更新時間：2023-09-19

梁逸歆
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

68Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

梁逸歆

List

99Cases

2021-10-22 - 2023-07-14

Phase II/III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2019-10-15 - 2024-05-28

Phase II/III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2021-03-15 - 2025-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2021-12-27 - 2026-01-17

Phase II/III

Active
A Phase 2/3 Study of Evorpacept (ALX148) in Patients With Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (ASPEN-06)

  • Condition/Disease

    Gastric Cancer

  • Test Drug

    輸注液

Participate Sites
7Sites

Recruiting7Sites

2023-10-05 - 2027-12-31

Phase II

Active
A Randomized, Multicenter, Double-blind, Phase II Study to Compare the Efficacy and Safety of the Treatment With ONO-4578 in Combination With Nivolumab, Fluoropyrimidine-based and Platinum- Based Chemotherapy (Hereinafter Referred to as Chemotherapy) With Those of the Treatment With Placebo in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

  • Condition/Disease

    Gastric Cancer

  • Test Drug

    ONO-4578

Participate Sites
6Sites

Recruiting6Sites

2022-03-25 - 2026-12-31

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2021-12-01 - 2025-07-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2024-05-15 - 2030-12-31

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2024-11-01 - 2028-09-30

Phase I

Active
An Open-Label, Multicenter, Phase 1 Study of AN4005 in Patients with Advanced Tumors

  • Condition/Disease

    Advanced Tumors

  • Test Drug

    tablets

Participate Sites
7Sites

Not yet recruiting5Sites

Recruiting2Sites

2022-04-01 - 2028-02-28

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

1 4 5 6 7 8 10
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB